Antibody Therapeutics

???? Year-end Gift: 50% APC (Article Processing Charge) Discount! ?? ?? For a limited time through 30 June 2025, all submitting authors are eligible to receive a 50% APC (publication fee) discount for their manuscripts to be submitted to Antibody Therapeutics. Corresponding authors who are members of the Chinese Antibody Society are eligible for this discount as well as new authors. For more information about why publish your research with Antibody Therapeutics, please visit: https://lnkd.in/eP9nFpMa Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics

We would like to feature the excellent review article published in Antibody Therapeutics with the title of “Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate”. Substantial therapeutic efficacy of antibody-drug conjugates (ADCs) has been validated through approvals of 16 ADCs for the treatment of malignant tumors. To resolve the hurdle of suboptimal tumor penetration, miniaturized antibody fragments with engineered formats have been harnessed for ADC assembly. By virtue of their reduced molecular sizes, antibody fragment-drug conjugates hold considerable promise for efficacious delivery of cytotoxic agents, thus conferring superior therapeutic outcomes. This review focus on current advancements in novel ADC development utilizing smaller antibody formats from ~6 to 80?kDa, with particular emphasis on single-domain antibodies, which have been widely applied in novel ADC design. Additionally, strategies to optimize clinical translation are discussed, including half-life extension, acceleration of internalization, and reduction of immunogenic potential. The corresponding author is Yanling Wu from Fudan University. Open access to the paper at https://lnkd.in/eDFykmBP Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #mAb #ADC

We would like to feature the excellent article published in Antibody Therapeutics with the title of “First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region”. Recent approvals of frunevetmab and bedinvetmab signal new horizons for antibody treatments for animals, especially for animals of economic importance with unmet need (e.g., goats). To bridge the current knowledge gap in goat antibody structure and derivatization, researchers from Takeda and Northeastern University present a novel method to site-specifically modify native goat antibodies via glycan remodeling. The corresponding author are Michael Dolan (Takeda), Sheldon Oppenheim (Takeda) and Zhaohui Sunny Zhou (Northeastern University). Open access to the paper at https://lnkd.in/ezpPZszs Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #ADC

We’d like to spotlight this excellent ADC research article published in Antibody Therapeutics with the title of “A disruptive clickable antibody design for the generation of antibody-drug conjugates”. This work describes for the first time to a ready-to-click antibody design based on non-canonical amino acids enabling the generation of highly hydrophilic antibody-drug conjugates and highlights the importance of the conjugation site selection as well as the drug-linker design for the generation of less hydrophobic antibody-drug conjugates. The author of this paper are Nathana?l Rakotoarinoro, Yan F K Dyck, Simon Krebs, Miriam-Kousso Assi, Maria Kristina Parr, and Marlitt Stech from multiple universities in Germany. Open access to this paper at: https://lnkd.in/d6mtE4RY Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #ADC

We thank evitria AG very much for featuring this interesting paper published in our journal.

Bispecific antibodies (bsAbs) are a fast-growing group of therapeutic antibodies. BsAb can simultaneously bind two different epitopes or antigens, allowing for multiple mechanistic functions with synergistic effects.?Antibody Therapeutics would like to highlight bispecific antibodies related articles. The 12th article is entitled “Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth” contributed by Kong Peng Lam, Yuansheng Yang, and Shengli Xu from A*STAR - Agency for Science, Technology and Research. In the study, researchers produced a T cell-redirecting BCMA-targeting bsAb that can robustly stimulate T cell proliferation and activation and effectively kill MM cells both?in vitro?and?in vivo. The BCMA bsAb has good potential to be developed into a therapeutic drug for MM treatment. Open access through ?https://lnkd.in/gcXHBrqn Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #mAb

Bispecific antibodies (bsAbs) are a fast-growing group of therapeutic antibodies. BsAb can simultaneously bind two different epitopes or antigens, allowing for multiple mechanistic functions with synergistic effects.?Antibody Therapeutics would like to highlight bispecific antibodies related articles. The 11th article is entitled “Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection” contributed by Minghua Li (Chinese Academy of Sciences) and Liusong Yin, PhD (SunHo Pharmaceutical). ISH0339 is a novel tetravalent broadly neutralizing bispecific antibody with long-term protection that has demonstrated excellent anti-SARS-CoV-2 activities against all widespread viral subtypes and favorable safety profile, with potential for both prophylactic and therapeutic purposes against emerging SARS-CoV-2 infection. Open access through https://lnkd.in/erbS8Pdg Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #BispecificAb #mAb

Bispecific antibodies (bsAbs) are a fast-growing group of therapeutic antibodies. BsAb can simultaneously bind two different epitopes or antigens, allowing for multiple mechanistic functions with synergistic effects.?Antibody Therapeutics would like to highlight bispecific antibodies related articles. The 10th article is entitled “Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform” contributed by Haixiang (Harry) Yu and Sujun Deng from Jemincare. Researchers discovered a common light chain (CLC) bispecific antibody targeting PD-1 and PD-L1 with favorable biophysical properties and potent efficacy. Notably, they have developed a unique and flexible Hybridoma-to-Phage-to-Yeast platform for the generation of CLC bispecific antibodies targeting a given pair of targets. Open access through https://lnkd.in/gQswrnJx Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #mAb #BispecificAb

Bispecific antibodies (bsAbs) are a fast-growing group of therapeutic antibodies. BsAb can simultaneously bind two different epitopes or antigens, allowing for multiple mechanistic functions with synergistic effects.?Antibody Therapeutics would like to highlight bispecific antibodies related articles. The 9th article is entitled “Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies” contributed by Xin Yu and Lili Huang from AbbVie. Early assessment of antibody off-target binding is essential for mitigating developability risks such as fast clearance, reduced efficacy, toxicity, and immunogenicity. Researchers present the development of an ensemble of three deep learning models based on two pan-protein foundational protein language models (ESM2 and ProtT5) and an antibody-specific protein language model (PLM) (Antiberty). This study yields insights on building infrastructures to support machine learning activities and training models for critical assays in antibody discovery. Open access through https://lnkd.in/eW6eKN3v Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #mAb

Bispecific antibodies (bsAbs) are a fast-growing group of therapeutic antibodies. bsAb can simultaneously bind two different epitopes or antigens, allowing for multiple mechanistic functions with synergistic effects.?Antibody Therapeutics would like to highlight bispecific antibodies related articles. The 8th article is entitled “A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications” contributed by Zhiqiang Chen (D3 Bio) and Jianqing Xu (WuXi Biologics). This article presents a case study addressing agitation-induced aggregation of a bispecific antibody via protein engineering. Detailed process including root cause identification, rational design strategies and wet-lab validation is introduced. This study contributes the understanding of aggregation mechanism and offers insights into optimizing bispecific antibody stability for improved downstream applications. Open access through https://lnkd.in/gaTnm7BR Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. https://lnkd.in/gsTu_U2 #Antibody #Therapeutics #BispecificAb #mAb